A549细胞

【A549】A549细胞/A549细胞/A549人非小细胞肺癌细胞Cell line name A-549

Synonyms A 549; A549; NCI-A549; A549/ATCC; A549 ATCC; A549ATCC; hA549

Accession CVCL_0023

Secondary accession CVCL_H249

Resource Identification Initiative To cite this cell line use: A-549 (RRID:CVCL_0023)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: ENCODE project common cell types; tier 2.

Part of: JFCR39 cancer cell line panel.

Part of: KuDOS 95 cell line panel.

Part of: MD Anderson Cell Lines Project.

Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).

Part of: NCI-60 cancer cell line panel.

Part of: NCI-7 clinical proteomics reference material cell line panel.

Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-2000.

Population: Caucasian.

Characteristics: Expresses HPRT1 at the surface of the cell membrane (PubMed=28408844).

Virology: Highly susceptible to infection by Zika virus (ZIKV) (PubMed=29468137).

Doubling time: 18 hours (Note=In RPMI 1640 + 10% FBS), 37 hours (Note=In ACL-3), 36 hours (Note=In ACL-3+BSA) (PubMed=3940644); 27.0 hours (PubMed=8286010); 22 hours (PubMed=25984343); 23.9 hours (PubMed=29681454); 27 hours (Note=From cell counting), 27 hours (Note=From absorbance) (DOI=10.5897/IJBMBR2013.0154); 26.08 hours (PubMed=35976051); ~28 hours (CLS=300114); ~40 hours (DSMZ=ACC-107); 22.9 hours (NCI-DTP=A549).

Microsatellite instability: Stable (MSS) (PubMed=12661003; Sanger).

Omics: Acetylation analysis by proteomics.

Omics: Array-based CGH.

Omics: CNV analysis.

Omics: CTCF ChIP-seq epigenome analysis.

Omics: H3K4me3 ChIP-seq epigenome analysis.

Omics: H3K9ac ChIP-seq epigenome analysis.

Omics: CRISPR phenotypic screen.

Omics: Deep antibody staining analysis.

Omics: Deep exome analysis.

Omics: Deep membrane proteome analysis.

Omics: Deep phosphoproteome analysis.

Omics: Deep proteome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Fluorescence phenotype profiling.

Omics: lncRNA expression profiling.

Omics: Metabolome analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: Proteome analysis by 2D-DE/MS.

Omics: shRNA library screening.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Omics: Virome analysis using proteomics.

Misspelling: A59; PubMed=16354588.

Misspelling: A594; Note=In abstract of PubMed=18227028.

Derived from site: In situ; Lung; UBERON=UBERON_0002048.

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342; PMCID=PMC4893961

Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.

The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.

Cancer Res. 73:4372-4382(2013)

 

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018

Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C., Wilhelm M., Kuster B.

Global proteome analysis of the NCI-60 cell line panel.

Cell Rep. 4:609-620(2013)

 

PubMed=24135919; DOI=10.1038/ncomms3617; PMCID=PMC4107456

Balbin O.A., Prensner J.R., Sahu A., Yocum A., Shankar S., Malik R., Fermin D., Dhanasekaran S.M., Chandler B., Thomas D., Beer D.G., Cao X.-H., Nesvizhskii A.I., Chinnaiyan A.M.

Reconstructing targetable pathways in lung cancer by integrating diverse omics data.

Nat. Commun. 4:2617.1-2617.13(2013)

 

PubMed=24279929; DOI=10.1186/2049-3002-1-20; PMCID=PMC4178206

Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.

The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.

Cancer Metab. 1:20.1-20.13(2013)

 

PubMed=24618588; DOI=10.1371/journal.pone.0091433; PMCID=PMC3950186

Chernobrovkin A.L., Zubarev R.A.

Detection of viral proteins in human cells lines by xeno-proteomics: elimination of the last valid excuse for not testing every cellular proteome dataset for viral proteins.

PLoS ONE 9:E91433-E91433(2014)

 

PubMed=24670534; DOI=10.1371/journal.pone.0092047; PMCID=PMC3966786

Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.

High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.

PLoS ONE 9:E92047-E92047(2014)

 

PubMed=25120651; DOI=10.3892/ol.2014.2234; PMCID=PMC4114630

Suzuki M., Ikeda K., Shiraishi K., Eguchi A., Mori T., Yoshimoto K., Shibata H., Ito T., Baba Y., Baba H.

Aberrant methylation and silencing of IRF8 expression in non-small cell lung cancer.

Oncol. Lett. 8:1025-1030(2014)

 

PubMed=25475639; DOI=10.5731/pdajpst.2014.01027

Shabram P., Kolman J.L.

Evaluation of A549 as a new vaccine cell substrate: digging deeper with massively parallel sequencing.

PDA J. Pharm. Sci. Technol. 68:639-650(2014)

 

PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

OncoImmunology 3:e954893.1-e954893.12(2014)